Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c

Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• DA Davidson Reiterates Buy Rating on CrowdStrike (CRWD) Ahead of User Conference
• Yatsen Holding (YSG) Reports Q2 Loss of $0.16